BriaCell Competitors

BCTXW Stock  USD 0.34  0.06  18.97%   
BriaCell Therapeutics competes with Bright Minds, HP, Intel, Chevron Corp, and Coca Cola; as well as few others. The company classifies itself under Biotechnology sector and is part of Health Care industry. Analyzing BriaCell Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BriaCell Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out BriaCell Therapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of BriaCell Therapeutics competition on your existing holdings.
  
Return On Equity is likely to climb to 5.08 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.64). At this time, BriaCell Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.2 M in 2024.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BriaCell Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.020.3811.94
Details
Intrinsic
Valuation
LowRealHigh
0.010.2711.83
Details
Naive
Forecast
LowNextHigh
0.010.3411.90
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.250.310.36
Details

BriaCell Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BriaCell Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BriaCell and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BriaCell Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
JNJKO
JPMCVX
TRVDRUG
INTCHPQ
CVXHPQ
CVXINTC
  
High negative correlations   
JPMKO
JNJCVX
KOCVX
JNJINTC
KODRUG
JPMJNJ

Risk-Adjusted Indicators

There is a big difference between BriaCell Stock performing well and BriaCell Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BriaCell Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare BriaCell Therapeutics and related stocks such as Bright Minds Biosciences, HP Inc, and Intel Net Income Over Time
Select Fundamental
Price To Sales RatioPtb Ratio
Days Sales OutstandingBook Value Per Share
Free Cash Flow YieldInvested Capital
Operating Cash Flow Per ShareAverage Payables
Stock Based Compensation To RevenueCapex To Depreciation
Pb RatioEv To Sales
Free Cash Flow Per ShareInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Sales General And Administrative To RevenueAverage Inventory
Research And Ddevelopement To RevenueCapex To Revenue
Cash Per SharePocfratio
Interest CoveragePayout Ratio
Capex To Operating Cash FlowPfcf Ratio
Days Payables OutstandingNet Current Asset Value
Income QualityTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Ev To Free Cash FlowIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareGraham Number
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D ADividend Yield
RoicPayables Turnover
RoeReturn On Tangible Assets
Earnings YieldReceivables Turnover
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Capital EmployedFixed Asset Turnover
Return On AssetsAsset Turnover
Return On Equity
201020112012201320142015201620172018201920202021202220232024
DRUG(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(78.7 K)(485.9 K)(8.5 M)(15.2 M)(7.4 M)(6.6 M)(7 M)
HPQ489 M(12.7 B)5.1 BB4.6 B2.5 B2.5 B5.3 B3.2 B2.8 B6.5 B3.1 B3.3 B3.8 B3.1 B
INTC1.6 M12.9 B11 B9.6 B11.7 B11.4 B10.3 B9.6 B21.1 B21 B20.9 B19.9 BB1.7 B1.6 B
CVX1.6 B26.9 B26.2 B21.4 B19.2 B4.6 B(497 M)9.2 B14.8 B2.9 B(5.5 B)15.6 B35.5 B21.4 B11.3 B
KO722.3 M8.6 BB8.6 B7.1 B7.4 B6.5 B1.2 B6.4 B8.9 B7.7 B9.8 B9.5 B10.7 B5.4 B
TRV45.4 M1.4 B2.5 B3.7 B3.7 B3.4 BB2.1 B2.5 B2.6 B2.7 B3.7 B2.8 BB1.8 B
JNJ613.7 M9.7 B10.9 B13.8 B16.3 B15.4 B16.5 B1.3 B15.3 B15.1 B14.7 B20.9 B17.9 B35.2 B36.9 B
JPM390.2 M19 B21.3 B17.9 B21.7 B24.4 B24.7 B24.4 B32.5 B36.4 B29.1 B48.3 B37.7 B49.6 B52 B
MSFT39.3 M17 B21.9 B22.1 B12.2 B20.5 B25.5 B16.6 B39.2 B44.3 B61.3 B72.7 B72.4 B88.1 B92.5 B

BriaCell Therapeutics and related stocks such as Bright Minds Biosciences, HP Inc, and Intel Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in BriaCell Therapeutics financial statement analysis. It represents the amount of money remaining after all of BriaCell Therapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

BriaCell Therapeutics Competitive Analysis

The better you understand BriaCell Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BriaCell Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BriaCell Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BCTXW DRUG HPQ INTC CVX KO TRV JNJ JPM MSFT
 18.97 
 0.34 
BriaCell
 2.81 
 39.18 
Bright
 11.36 
 34.66 
HP
 1.66 
 23.65 
Intel
 0.26 
 162.11 
Chevron
 0.19 
 64.43 
Coca
 1.10 
 266.66 
Travelers
 0.57 
 155.40 
Johnson
 0.07 
 249.79 
JPMorgan
 1.17 
 422.99 
Microsoft
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Current Valuation
Price To Book
Operating Margin
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Target Price
Debt To Equity
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Day Typical Price
Accumulation Distribution
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Relative Strength Index
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

BriaCell Therapeutics Competition Performance Charts

Five steps to successful analysis of BriaCell Therapeutics Competition

BriaCell Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BriaCell Therapeutics in relation to its competition. BriaCell Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BriaCell Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BriaCell Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BriaCell Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BriaCell Therapeutics position

In addition to having BriaCell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Disruptive Technologies Thematic Idea Now

Disruptive Technologies
Disruptive Technologies Theme
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.